New drug combo aims to fight advanced cancers in first human trial

NCT ID NCT07607678

Recruiting now Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 4 times

Summary

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 participants will receive different doses and be monitored for up to 2 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID CANCER METASTATIC SOLID CANCER UNRESECTABLE ADVANCED OR METASTATIC SOLID CANCER

Contacts and locations

Locations

Clínica Universidad de Navarra
RECRUITING

Pamplona, 31008, Spain
Hackensack University Medical Center
NOT_YET_RECRUITING

Hackensack, New Jersey, 07601, United States
Hospital Clinico Universitario de Valencia
RECRUITING

Valencia, 46010, Spain
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
National Cancer Center Hospital
RECRUITING

Tokyo, Chuo-ku, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Chiba, Kashiwa, 277-8577, Japan
New York University Langone Medical Center
NOT_YET_RECRUITING

New York, New York, 10016, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.